Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 9/20 | 0.68 |
| ▸ | PKM | P14618 | 5/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17707671 | 0.85 | EPHX2 (0.50) | EPHX2PKMKMT2ATRPV4SMN1; SMN2 | |
| SCHEMBL14902768 | 0.81 | EPHX2 (1.00) | EPHX2PKMKMT2A | |
| SCHEMBL14920210 | 0.81 | EPHX2 (0.52) | EPHX2TRPV4HTT | |
| SCHEMBL14902779 | 0.73 | EPHX2 (0.82) | EPHX2 | |
| SCHEMBL16200782 | 0.72 | EPHX2 (0.81) | EPHX2 | |
| SCHEMBL14892920 | 0.72 | EPHX2 (1.00) | EPHX2 | |
| SCHEMBL14902796 | 0.71 | EPHX2 (0.74) | EPHX2 | |
| SCHEMBL30306676 | 0.70 | EPHX1 (0.49) | EPHX2PKMKMT2AMEN1 | |
| SCHEMBL26764345 | 0.70 | EPHX1 (0.49) | EPHX2PKMKMT2AMEN1 | |
| SCHEMBL23850293 | 0.69 | EPHX2 (0.47) | EPHX2PKMKMT2ATRPV4SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773644-B1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | claimed |
| US-9139593-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2015-09-22 | — | — | US | claimed |
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFMANN-LA ROCHE AG (CH) | 2014-10-30 | — | — | US | claimed |
| EP-2773644-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | claimed |
| WO-2013064467-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | claimed |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | claimed |
| EP-2773644-B1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | HOFFMANN LA ROCHE (CH) | 2016-05-04 | — | — | EP | disclosed |
| US-9139593-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | F. HOFMANN-LA ROCHE AG (CH) | 2014-10-30 | — | — | US | disclosed |
| EP-2773644-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-8809552-B2 | Azetidine compounds, compositions and methods of use | HOFFMANN-LA ROCHE INC. (US) | 2014-08-19 | — | — | US | disclosed |
| WO-2013064467-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND THEIR USE AS INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | HOFFMANN-LA ROCHE INC. (US) | 2013-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323462-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EPHX1, EPHX2, HRH2 | EPHX2 2/4885PKM 3579/4885KMT2A 3111/4885 |
| US-20130109668-A1 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | EPHX1, EPHX2, HRH2 | EPHX2 2/4885PKM 3579/4885KMT2A 3111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.